278 related articles for article (PubMed ID: 17912639)
1. The patient experience.
Harbeck N; Haidinger R
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):91-103. PubMed ID: 17912639
[TBL] [Abstract][Full Text] [Related]
2. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Scott LJ; Keam SJ
Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
[TBL] [Abstract][Full Text] [Related]
3. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
4. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
5. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Koeberle D; Thuerlimann B
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):55-66. PubMed ID: 17912636
[TBL] [Abstract][Full Text] [Related]
6. A decade of letrozole: FACE.
O'Shaughnessy J
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
[TBL] [Abstract][Full Text] [Related]
7. Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Higa GM
Drugs; 2006; 66(3):363-4. PubMed ID: 16526828
[No Abstract] [Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
[TBL] [Abstract][Full Text] [Related]
11. Letrozole: advancing hormone therapy in breast cancer.
Lee RJ; Armstrong AC; Wardley AM
Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk of late recurrence in hormone-responsive breast cancer.
Cufer T
Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
[TBL] [Abstract][Full Text] [Related]
13. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
15. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
16. The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Pennery E
Eur J Oncol Nurs; 2008 Jul; 12(3):233-43. PubMed ID: 18372213
[TBL] [Abstract][Full Text] [Related]
17. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
18. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
19. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
Forciniti S
Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
[No Abstract] [Full Text] [Related]
20. Safety of aromatase inhibitors in the adjuvant setting.
Perez EA
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]